Novel therapeutic approaches for Epstein-Barr virus associated gastric cancer

Byung Woog Kang, Dong Won Baek, Hyojeung Kang, Jong Gwang Kim, Jin Ho Baek

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Epstein-Barr virus (EBV)-associated gastric cancer (GC) (EBVaGC) is classified as one of four GC subtypes by comprehensive molecular characterization. Though the mechanism of tumorigenesis by EBV infection has not yet been fully clarified, EBV infection might contribute to the malignant transformation of GC cells by involving various cellular processes and signaling pathways. EBVaGC has shown the following distinct characteristics in contrast to other subtypes: extreme DNA hypermethylation, recurrent phosphatidylinositol 4,5-biphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) mutations, overexpression of programmed cell death ligand 1/2 (PD-L1/2), and occasional immune cell signaling activation. Therefore, using these molecular features as guides, targeted agents need to be evaluated in clinical trials for EBVaGC. Accordingly, this review uses the best available evidence to focus on novel therapeutic approaches using the distinct pathologic characteristics of EBVaGC patients.

Original languageEnglish
Pages (from-to)4003-4010
Number of pages8
JournalAnticancer Research
Issue number8
StatePublished - 2019


  • Epstein-Barr virus
  • Gastric cancer
  • Review
  • Treatment


Dive into the research topics of 'Novel therapeutic approaches for Epstein-Barr virus associated gastric cancer'. Together they form a unique fingerprint.

Cite this